Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Capital Expenditures (2016 - 2025)

Apyx Medical (APYX) has disclosed Capital Expenditures for 15 consecutive years, with $275000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 12.24% year-over-year to $275000.0, compared with a TTM value of $1.1 million through Dec 2025, up 54.29%, and an annual FY2025 reading of $1.1 million, up 54.29% over the prior year.
  • Capital Expenditures was $275000.0 for Q4 2025 at Apyx Medical, down from $519000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $519000.0 in Q3 2025 and bottomed at $29000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $205100.0, with a median of $181000.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 1788.89% in 2021, while the deepest fall reached 69.15% in 2021.
  • Year by year, Capital Expenditures stood at $332000.0 in 2021, then tumbled by 57.23% to $142000.0 in 2022, then plummeted by 34.51% to $93000.0 in 2023, then soared by 163.44% to $245000.0 in 2024, then rose by 12.24% to $275000.0 in 2025.
  • Business Quant data shows Capital Expenditures for APYX at $275000.0 in Q4 2025, $519000.0 in Q3 2025, and $265000.0 in Q2 2025.